Hillsdale Investment Management Inc. Buys 41,150 Shares of CareDx, Inc (NASDAQ:CDNA)

Hillsdale Investment Management Inc. grew its stake in shares of CareDx, Inc (NASDAQ:CDNA) by 30.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,980 shares of the company’s stock after buying an additional 41,150 shares during the period. Hillsdale Investment Management Inc. owned approximately 0.33% of CareDx worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of CDNA. Quarry LP bought a new position in CareDx during the 3rd quarter worth approximately $27,000. Harvest Fund Management Co. Ltd bought a new position in shares of CareDx during the third quarter worth $52,000. KBC Group NV acquired a new position in shares of CareDx in the 3rd quarter valued at $99,000. Plato Investment Management Ltd increased its position in shares of CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after buying an additional 1,370 shares in the last quarter. Finally, Quest Partners LLC raised its stake in CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock worth $175,000 after buying an additional 1,540 shares during the period.

CareDx Stock Up 2.2 %

NASDAQ CDNA opened at $19.32 on Friday. The firm’s 50 day moving average is $21.79 and its 200-day moving average is $23.95. The company has a market capitalization of $1.07 billion, a PE ratio of -7.16 and a beta of 1.95. CareDx, Inc has a 12-month low of $7.42 and a 12-month high of $34.84.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. As a group, sell-side analysts expect that CareDx, Inc will post -0.9 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stephens reissued an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright lowered their target price on CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, CareDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.